腫瘍アブレーション市場：技術別、用途別、地域別、2024年～2031年

腫瘍アブレーション市場の評価、2024年～2031年

世界のがんの有病率の増加と低侵襲治療の技術進歩が、腫瘍アブレーションの需要を促進しています。高周波焼灼やマイクロ波焼灼のような技術を使用する腫瘍アブレーションは、特に外科的介入を受けることができない患者に、従来の手術に代わるものを提供します。これにより、腫瘍アブレーション市場は2023年に12億米ドルの収益を超え、2031年には約26億米ドルの評価に達すると予測されています。

腫瘍アブレーションは、周囲の組織に害を与えることなく腫瘍細胞を標的にして破壊する精度の高さが認められており、肝臓、肺、腎臓などの臓器の小さな腫瘍を治療するのに好まれています。同市場は、低侵襲手技に対する需要の高まりと技術の進歩により、2024年から2031年にかけてCAGR12.9％で成長すると予想されています。

腫瘍アブレーション市場定義/概要

腫瘍アブレーション術とは、従来の手術で腫瘍を切除することなく、がん細胞を破壊するために用いられる低侵襲処置を指します。この技術は、高周波、マイクロ波、冷凍アブレーションを含む様々な形態のエネルギーを使用して、がん細胞を破壊します。これらの技術は、特に年齢や健康状態、腫瘍の位置などの理由で手術の適応とならない患者を対象に、様々な種類のがんの治療に使用されるようになってきています。

腫瘍アブレーションには、回復時間の短縮、合併症の減少、外来での手術が可能などの利点があります。肝腫瘍、肺腫瘍、腎腫瘍、骨腫瘍の治療によく用いられています。個別化された低侵襲治療の選択肢に対する需要が高まる中、腫瘍アブレーション市場の将来は、画像誘導手技のさらなる進歩や、免疫療法や化学療法など他の治療法との統合にあります。

がん罹患率の増加は腫瘍アブレーション市場を牽引するか？

世界のがん罹患率の上昇、特に肝臓がん、肺がん、腎臓がんは、腫瘍アブレーション市場の重要な促進要因です。世界保健機関（WHO）によると、がん患者は2040年までに47％増加すると予想されており、治療オプションに対する需要の高まりにつながっています。腫瘍アブレーションは低侵襲で、手術に適さない患者も治療できるため、広く受け入れられています。

さらに、入院期間と回復時間を短縮する外来患者処置への嗜好の高まりが、腫瘍アブレーション技術の採用をさらに後押ししています。また、ヘルスケアインフラの改善やがんに対する意識の高まりを背景に、新興市場でのアブレーション技術の採用が増加していることも、市場の成長を後押しすると予想されます。

高い治療費と先端技術へのアクセス制限は腫瘍アブレーション市場の妨げになるか？

そのメリットにもかかわらず、腫瘍アブレーション市場は、治療費の高騰や新興国地域における先端技術へのアクセスの制限といった課題に直面しています。腫瘍アブレーションには専門的な機器と訓練を受けた専門家が必要であるため、低所得地域では治療費が高くなり、治療へのアクセスも悪くなります。このため、ヘルスケアシステムが未発達な地域では、腫瘍アブレーションの導入が制限されています。

さらに、いくつかの国では償還の問題があり、ヘルスケアプロバイダーや患者にとって大きな課題となっています。アブレーション装置の高額な費用と保険適用範囲の不一致が相まって、小規模の病院や診療所がこれらの治療を提供することを躊躇させ、市場の成長を鈍化させる可能性があります。

目次

第1章 世界の腫瘍アブレーション市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 腫瘍アブレーションの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 腫瘍アブレーションの世界市場：技術別

• 概要
• ラジオ波焼灼療法（RFA）
• マイクロ波アブレーション（MWA）
• クライオアブレーション
• その他の技術

第6章 腫瘍アブレーションの世界市場：用途別

• 概要
• 肝臓がん
• 肺がん
• 腎臓がん
• その他

第7章 腫瘍アブレーションの世界市場、地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の腫瘍アブレーション市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• Healthtronics, Inc.
• Medtronic, PLC.
• Sonacare Medical, LLC
• Boston Scientific Corporation
• Edap Tms S.A.
• Misonix, Inc.
• Galil Medical, Inc.
• Neuwave Medical, Inc.
• Mermaid Medical A/S
• Angiodynamics, Inc.

第10章 付録

• 関連調査

Tumor Ablation Market Valuation - 2024-2031

The growing prevalence of cancer worldwide, along with technological advancements in minimally invasive treatments, is driving the demand for tumor ablation procedures. Tumor ablation, which uses techniques like radiofrequency and microwave ablation, offers an alternative to traditional surgery, especially for patients unable to undergo surgical interventions. This has enabled the Tumor Ablation Market to exceed a revenue of USD 1.2 Billion in 2023 and is projected to reach a valuation of aroundUSD 2.6 Billion by 2031.

Tumor ablation is recognized for its precision in targeting and destroying tumor cells without harming surrounding tissues, making it a preferred choice for treating small tumors in organs like the liver, lungs, and kidneys. The market is expected to grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031 due to the increasing demand for minimally invasive procedures and technological advancements.

Tumor Ablation Market: Definition/ Overview

Tumor ablation refers to minimally invasive procedures used to destroy cancer cells without removing the tumor through traditional surgery. This technology uses different forms of energy, including radiofrequency, microwave, and cryoablation, to destroy cancer cells. These techniques are increasingly being used to treat various types of cancer, particularly in patients who are poor candidates for surgery due to age, health condition, or the tumor's location.

Tumor ablation offers several benefits including reduced recovery times, fewer complications, and the ability to perform the procedure on an outpatient basis. It is commonly used in treating liver, lung, kidney, and bone tumors. As demand for personalized, minimally invasive treatment options rises, the future of the Tumor Ablation Market lies in further advancements in image-guided procedures and integration with other treatment modalities like immunotherapy and chemotherapy.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Incidence of Cancer Drive the Tumor Ablation Market?

The rising global incidence of cancer, particularly liver, lung, and kidney cancers is a significant driver of the Tumor Ablation Market. According to the World Health Organization (WHO), cancer cases are expected to rise by 47% by 2040 leading to an increased demand for treatment options. Tumor ablation due to its minimally invasive nature and ability to treat patients who are not suitable for surgery is gaining widespread acceptance.

Moreover, the growing preference for outpatient procedures which reduce hospital stays and recovery times is further boosting the adoption of tumor ablation techniques. The increased adoption of ablation technologies in emerging markets driven by improved healthcare infrastructure and rising cancer awareness is also anticipated to fuel market growth.

Will High Treatment Costs and Limited Access to Advanced Technologies Hamper the Tumor Ablation Market?

Despite its benefits, the Tumor Ablation Market faces challenges including high treatment costs and limited access to advanced technologies in developing regions. Tumor ablation procedures require specialized equipment and trained professionals which can make these treatments costly and less accessible in low-income areas. This limits the adoption of tumor ablation in regions with less-developed healthcare systems.

Furthermore, reimbursement issues in several countries pose a significant challenge for healthcare providers and patients. The high cost of ablation equipment, combined with inconsistent insurance coverage, may deter smaller hospitals and clinics from offering these treatments, potentially slowing market growth.

Category-Wise Acumens

Will Radiofrequency Ablation Continue to Dominate the Tumor Ablation Market?

Radiofrequency ablation (RFA) remains the most widely used technology in tumor ablation due to its proven efficacy and safety. RFA works by generating heat to destroy cancer cells, and it is particularly effective in treating liver and lung tumors. As it offers precise control over the ablation area minimizing damage to surrounding tissues, it continues to be a preferred method in oncology. Meanwhile, microwave ablation is rapidly gaining popularity due to its ability to create larger ablation zones making it suitable for larger tumors. Cryoablation which involves freezing the tumor cells is also gaining traction, particularly in treating kidney and prostate cancers.

While RFA is expected to remain the primary treatment, new technologies like as microwave ablation (MWA) and cryoablation are gaining interest and may challenge its dominance. MWA has benefits such as quicker treatment periods and the potential to treat larger tumors which may be appealing to both physicians and patients. Similarly, cryoablation is being investigated for its unique capacity to freeze tumors which could offer an alternative for certain patient profiles. As these technologies progress and clinical evidence for their efficacy grows, they may acquire a sizable share of the tumor ablation industry.

Will the Increasing Adoption of Tumor Ablation in Liver Cancer Treatment Drive the Market?

Liver cancer is one of the most common cancers treated with tumor ablation, and this trend is expected to continue driving market growth. The rising incidence of liver cancer, particularly in Asia-Pacific and North America is boosting the demand for ablation therapies. Tumor ablation is especially beneficial for patients with early-stage liver cancer who are not eligible for surgery. Furthermore, Lung cancer is another significant application area for tumor ablation, particularly for patients with inoperable or recurrent tumors. As healthcare providers increasingly adopt minimally invasive procedures to reduce recovery times and complications, the use of tumor ablation in lung and kidney cancer treatment is expected to rise during the forecast period.

Furthermore, advances in technology are improving the efficacy and precision of tumor ablation techniques. The development of image-guided procedures such as ultrasound and computed tomography (CT) guidance enables more precise tumor targeting, increasing treatment outcomes. As hospitals and clinics engage in updating their facilities with these new technologies, tumor ablation will become more accessible accelerating market growth. Regulatory approvals and clinical research demonstrating the safety and efficacy of these procedures boost confidence among healthcare practitioners and patients, resulting in higher adoption rates.

Country/Region-wise Acumens

Will Advancements in Healthcare Infrastructure Drive the North American Market?

The North American Tumor Ablation Market is projected to remain the largest regional market due to the region's advanced healthcare infrastructure and increasing adoption of innovative technologies. The U.S. leads the market driven by high healthcare spending, a large patient population, and the presence of key industry players. The increasing prevalence of liver, lung, and kidney cancers coupled with rising awareness about minimally invasive treatments is further propelling market growth.

Furthermore, favorable reimbursement policies and ongoing research in tumor ablation technologies are supporting the market in North America. The growing use of image-guided ablation techniques, such as MRI and CT scans to improve precision in tumor targeting is expected to drive further adoption of tumor ablation therapies.

Will Rising Cancer Incidence Fuel the Market in Asia Pacific?

The Asia Pacific region is expected to witness the highest growth in the Tumor Ablation Market due to the rising incidence of cancer and increasing healthcare investments. Countries such as China, Japan, and India are seeing a surge in cancer cases, particularly liver and lung cancer, which is fueling the demand for tumor ablation procedures. Moreover, government initiatives to improve healthcare access and the growing availability of advanced medical technologies are boosting market growth.

The growing adoption of ablation procedures in the Asia Pacific region is also driven by the growing demand for minimally invasive treatments and the rising awareness of their benefits among patients and healthcare providers. As healthcare infrastructure in emerging economies continues to improve, the Tumor Ablation Market is expected to expand significantly in this region.

Competitive Landscape

The Tumor Ablation Market is characterized by a mix of established and emerging players, each focusing on technological advancements, strategic partnerships, and product innovations to maintain a competitive edge. Companies are investing in developing new ablation technologies that offer improved precision, safety, and patient outcomes.

Some of the prominent players in the Tumor Ablation Market include:

Boston Scientific Corporation, Medtronic PLC, AngioDynamics, Inc., Merit Medical Systems, Johnson & Johnson (Ethicon), EDAP TMS S.A., IceCure Medical Ltd., RF Medical Co. Ltd., Neuwave Medical, Inc. (Johnson & Johnson).

Latest Developments

In June 2023, Boston Scientific launched a next-generation microwave ablation system designed to target larger tumors while minimizing damage to healthy tissues.

In October 2022, Medtronic announced its acquisition of an advanced cryoablation technology company to expand its portfolio in tumor ablation treatments.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TUMOR ABLATION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL TUMOR ABLATION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY

• 5.1 Overview
• 5.2 Radiofrequency Ablation (RFA)
• 5.3 Microwave Ablation (MWA)
• 5.4 Cryoablation
• 5.5 Other Technologies

6 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Liver Cancer
• 6.3 Lung Cancer
• 6.4 Kidney Cancer
• 6.5 Others

7 GLOBAL TUMOR ABLATION MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL TUMOR ABLATION MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Healthtronics, Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Medtronic, PLC.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Sonacare Medical, LLC
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Boston Scientific Corporation
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Edap Tms S.A.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Misonix, Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Galil Medical, Inc.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Neuwave Medical, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Mermaid Medical A/S
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Angiodynamics, Inc.
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research